





an Open Access Journal by MDPI

# Advanced Therapy Medicinal Products for Eye Diseases: Goals and Challenges

Guest Editors:

#### Prof. Dr. Yolanda Diebold

### Dr. Laura García-Posadas

Instituto Universitario de Oftalmobiología Aplicada (IOBA), Universidad de Valladolid, Paseo de Belén 17, 47011 Valladolid, Spain

Deadline for manuscript submissions: closed (1 July 2021)

## **Message from the Guest Editors**

Dear Colleagues,

The concept of advanced therapy medicinal products (ATMPs) encompasses novel kinds of medicines for human use that are based on genes, cells or tissues. Gene therapy, cell therapy, and tissue engineering are the main areas in which promising advanced therapies are emerging. The eve is a very complex organ whose main structures, the cornea and the retina, play a pivotal role in maintaining normal vision, as severe alterations in these tissues can lead to blindness. Ocular tissues are starting to benefit from ATMPs to fight the enormous complexity and devastating potential of many ocular diseases. However, developments arising from this field of work face important challenges related to vectors to deliver drugs and genetic material to target tissues, suitable biomaterials to prepare cell scaffolds, and cell stemness, among others, not to mention the complicated legislation around ATMPs.

This Special Issue serves as an overview of the current progress in the application of cell and gene therapies as well as tissue engineering to restore functionality in diseased ocular structures and the challenges they deal with to reach patients.







IMPACT FACTOR 4.9





an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

## **Message from the Editor-in-Chief**

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

### **Contact Us**